And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Right now, there isn’t a cure for people with dementia. But hope is on the horizon with lecanemab and donanemab – the first Alzheimer’s treatments licensed in Britain that can slow down the disease, ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The United States accounted for the highest market size of MCI, approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets, i.e., EU4 countries (Germany, ...

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

I have a special interest in Alzheimer’s disease. For nearly 25 years, I practiced general neurology in Portland, Oregon, and ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed. This ...